Contineum Therapeutics Inc (CTNM) FinancialsCTNMContineum Therapeutics Inc

Evaluating the bottom line, Contineum Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -28.01%, provide a clear picture of how effectively CTNM converts its operational activities into shareholder value.

In the context of the broader market, CTNM competes directly with industry leaders such as NAUT and PRLD. With a market capitalization of $318.27M, it holds a significant position in the sector. When comparing efficiency, CTNM's gross margin of N/A stands against NAUT's 92.11% and PRLD's 100.00%. Such benchmarking helps identify whether Contineum Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The financial performance of CTNM shows consistent losses, with a net income of -$14,456,000 in Q1 2026 and an EPS of -0.39. The company has a current ratio of 37.17, indicating strong liquidity, but ongoing losses raise concerns about sustainability.